Medeon

SEQ_NO	1	Date of announcement	2026/09/18	Time of announcement	15:15:08
Subject	The Board of Medeon has approved the execution of the Cross-Seal Settlement and Termination Agreement with Terumo
Date of events	2026/09/18	To which item it meets	paragraph 53
Statement	1.Date of occurrence of the event:2026/09/18 2.Company name:Medeon Biodesign, Inc. 3.Relationship to the Company (please enter ‘head office’ or ‘subsidiaries’):Head Office 4.Reciprocal shareholding ratios:Not Applicable 5.Cause of occurrence: Since the Company executed the Cross-Seal Asset Purchase Agreement with Terumo in March 2018, both parties have maintained a friendly and close collaborative relationship. However, due to the impact of the pandemic and supply chain challenges during this period, the launch schedule for Cross- Seal was delayed, making it difficult to achieve the original objectives. Consequently, Terumo issued a ‘Milestone Abandonment Notice’ in May 2025, resulting in the discontinuation of this project under the Agreement. Since May 2025, both parties actively sought constructive and mutually beneficial solutions, while maintaining a strong working relationship and communication foundation to sustain flexibility for future collaborations. After one year and four months of discussions, the parties have reached a final agreement that Medeon will receive a settlement amount of $6 million US Dollars, all milestones specified in the Asset Purchase Agreement will then be abandoned, and the relevant service agreements will be terminated. The milestone payments previously received were for milestones already achieved and are therefore non-refundable. 6.Countermeasures:To publish this announcement. 7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The Company has not previously recognized revenue for milestones that have not yet been achieved; upon completion of the settlement agreement, the Company will then recognize revenue in accordance with relevant accounting standards.